The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Alzheimer's disease drug development pipeline: 2018
Open accessAbstract
Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease‐modifying agent trials and 17 disease‐modifying agent trials in phase II. Twenty‐one trials of disease‐modifying agents in phase II did not require biomarker confirmation for AD at trial entry. Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the literature review reveals that only a single cholinesterase inhibitor is in Phase II and Phase III clinical trials, for AD management [147,148].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [148]
In the citing paper
“A number of additional pathogenic mechanisms have been described, possibly overlapping with Aβ plaques and NFT formation or induced by them, including inflammation, oxidative damage, iron deregulation, and cholesterol metabolism blood-brain barrier (BBB) dysfunction or α-synuclein toxicity.9-13”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Research works printed but not linked: 1
- Lombardo I., 2017, Results from the phase 3 MINDSET STUDY: a global, double‐blind, placebo‐controlled study of intepirdine in mild‐to‐moderate Alzheimer's disease
Cited by
Sorted by citations
Items 501–600 of 701
Leri, M., Vasarri, M., Palazzi, L., Barletta, E., Nielsen, E., Bucciantini, M., & Degl’Innocenti, D. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111626 · Cited by 7
Liu, Y., Kang, K., Lin, Y., & Wu, Y. (2020) · PubMed Central · Cited by 7
Liu, H., Kuo, Y., Cheng, J., Chang, L.-Z., Chang, M.-S., Su, L., Chuang, T.-N., & Lin, W. (2021) · Molecules · doi:10.3390/molecules26175338 · Cited by 7
Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 7
Misfolded proteins as a therapeutic target in Alzheimer's disease
Liyanage, S. I., & Weaver, D. F. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.003 · Cited by 8
Narang, S. S., Goyal, D., & Goyal, B. (2019) · Amino Acids · doi:10.1007/s00726-019-02797-0 · Cited by 7
Zhou, Y., Chen, S., Qiao, J., Cui, Y., Yuan, C., He, L., & Ouyang, J. (2019) · Journal of Mass Spectrometry · doi:10.1002/jms.4463 · Cited by 7
Murata, S., Ono, R., Yasuda, H., Tanemura, R., Kido, Y., & Kowa, H. (2021) · Physical Therapy Research · doi:10.1298/ptr.e10057 · Cited by 7
Kim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
Yerlikaya, P. O., Arısan, E. D., Gürkan, A. Ç., Okumus, O. O., Yazıcı, T. Y., Özbey, U., Kara, M., & Palavan-Ünsal, N. (2021) · Amino Acids · doi:10.1007/s00726-021-03027-2 · Cited by 7
Fecal Microbiota Transplantation Decreases Amyloid Load and Improves Cognition in Alzheimer’sPreprint
Elangovan, S., Borody, T. J., & Holsinger, R. M. D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/687376 · Cited by 7
Charpignon, M., Vakulenko‐Lagun, B., Zheng, B., Magdamo, C., Su, B., Evans, K. E., Rodriguez, S., Sokolov, A., Boswell, S. A., Sheu, Y.-H., et al. (2021) · medRxiv · doi:10.1101/2021.08.10.21261747 · Cited by 7
Li, F., Eteleeb, A. M., Buchser, W., Wang, G., Xiong, C., Payne, P., McDade, E., Karch, C. M. M., Harari, O., & Cruchaga, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458295 · Cited by 7
Deciphering T Cell Dynamics in Alzheimer's Disease Pathogenesis: Insights and Implications
Yang, Q., Qiu, Y., Ni, J., Li, H., & Qing, H. (2025) · Current Neuropharmacology · doi:10.2174/011570159x350611250303044527 · Cited by 7
Bilginer-Kartal, R., & Yıldız, A. A. (2025) · Macromolecular Bioscience · doi:10.1002/mabi.202400658 · Cited by 6
Li, L. Y., Park, E., He, C., Abbasi, A. Z., Zhi, P., Fraser, P. E., Rauth, A. M., Henderson, J. T., & Wu, X. Y. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501648 · Cited by 7
Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine
Maisam, M., Khan, M. T., Lodhi, M. S., Mou, K., Liu, Z., & Wei, D. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810258 · Cited by 7
Arunachalam, M., Chiranjeev, C., Mondal, B., & Sanjay, T. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-3731-8.ch017 · Cited by 6
I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies
Messmer, M. F., Wilhelm, E. E., & Shoulson, I. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1528 · Cited by 6
Next steps after diagnosing dementia: interventions to help patients and families
Bayer, A. J. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002416 · Cited by 6
Tsai, Y.-C., Luo, J.-C., Liu, T., Lu, I.-L., Shen, M., Chuang, C., Chern, C., & Chiu, H. (2020) · Nanomaterials · doi:10.3390/nano10071284 · Cited by 6
Multifunctional Ligand Approach: Search for Effective Therapy Against Alzheimer’s Disease
Pasieka, A., Panek, D., & Malawska, B. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch11 · Cited by 6
Neurodegeneration and the pharmacotherapeutic aspect of Alzheimer's disease
Binert-Kusztal, Ż., Starek, M., & Dąbrowska, M. (2021) · Farmacja Polska · doi:10.32383/farmpol/142108 · Cited by 6
Alzheimer’s Disease: Perspective on Therapeutic Options and Recent Hallmarks in Clinical Research
MOLLY, B. A., Seethamraju, S. M., & Nori, L. P. (2021) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/vic6sagcyq · Cited by 6
Igarashi, T., Umeda‐Kameyama, Y., Kojima, T., Akishita, M., & Nihei, M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1145314 · Cited by 6
Ma, S., Xia, T., Wang, X., & Wang, H. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1139789 · Cited by 6
Molecular modeling of cardanol-derived AChE inhibitors
Silva, M. D. A., Sette, C. D. B., Kiametis, A. S., Romeiro, L. A. S., & Gargano, R. (2019) · Chemical Physics Letters · doi:10.1016/j.cplett.2019.07.019 · Cited by 6
Selection of mutant µplasmin for amyloid-β cleavage in vivo
Yang, D., Zhu, W., Wang, Y., Tan, F., Ma, Z., Gao, J., & Lin, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-69079-8 · Cited by 7
Song, Y., Cui, H., Zhang, T., Yang, T., Li, X., & Xuan, P. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3089692 · Cited by 6
Kozin, S. A., Polshakov, V. I., Mezentsev, Y. V., Ivanov, A. S., Жохов, С. С., Юринская, М. М., Винокуров, М. Г., Makarov, A. А., & Mitkevich, V. A. (2018) · Molecular Biology · doi:10.1134/s0026898418040109 · Cited by 6
What are we trying to prevent in Alzheimer disease?
Jessen, F. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/fjessen · Cited by 6
Caneus, J., Autar, K., Akanda, N., Grillo, M., Long, C. J., Jackson, M., Lindquist, S., Guo, X., Morgan, D., & Hickman, J. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-73869-9 · Cited by 6
Sukanya, S., Bellver‐Sanchís, A., Choudhary, B. S., Kumar, S., Pérez, B., Martínez, A. L., Brea, J. M., Escolano, C., Griñán‐Ferré, C., & Malik, R. (2025) · Drug Development Research · doi:10.1002/ddr.70112 · Cited by 5
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
Maboko, L., Theron, A., Panayides, J., Cordier, W., Fisher, D., & Steenkamp, V. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70043 · Cited by 5
Liang, P., Wang, C. Y. Y., Liu, J., Huang, H., Li, Y., Kang, J., Li, G., & Wu, H. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70166 · Cited by 5
Predicted economic damage from a quick, simple Alzheimer's disease cure
Norins, L. C. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109398 · Cited by 5
Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer’s Disease
Tu, L. M. T. P. P. L. M., Hoang, T. X., Thu, V. T. A., Kim, J. Y., Lee, S.-M., Cho, W. W., Kim, Y. H., Choi, S. H., & Cho, S. (2020) · Diagnostics · doi:10.3390/diagnostics10110913 · Cited by 5
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Jang, B.-G., Choi, B., Kim, S., Lee, D.-S., Lee, J., Koh, Y. H., Jo, S. A., Kim, J., Kang, T., & Kim, M.-J. (2022) · Cells · doi:10.3390/cells11162585 · Cited by 5
Ensemble Model for Predicting Alzheimer's Disease and Disease Stages with CNN and Transformer Models
Chen, W., Sun, F., Luo, Y., & Wang, X. (2023) · International Conference on Algorithms, Data Mining, and Information Technology (ADMIT) · doi:10.1145/3625403.3625414 · Cited by 5
Tang, R., Jian, Y., Hu, Z., Li, L., Wang, H., Miao, P., Yang, Z., & Tang, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169036 · Cited by 5
Camins, A., Ettcheto, M., Busquets, O., Manzine, P. R., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., Sureda, F. X., Bulló, M., Olloquequi, J., et al. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552677 · Cited by 5
Fei, X., Yu, Y., Di, Y., Ai, L., Yao, D., Bai, S., Zhao, S., Lyu, J., Cai, X., He, R., et al. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23130 · Cited by 5
Tolomeu, H. V., & Fraga, C. A. M. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210820092220 · Cited by 5
Gedächtnisambulanzstrukturen in Deutschland – Ergebnisse einer Klinikbefragung
Meiberth, D. U., Rapp, M. A., & Jessen, F. (2019) · Psychiatrische Praxis · doi:10.1055/a-0825-9049 · Cited by 5
Testing the Neuroprotective Properties of PCSO-524® Using a Neuronal Cell Cycle Suppression Assay
Zhu, B., Zhang, Y., & Herrup, K. (2019) · Marine Drugs · doi:10.3390/md17020079 · Cited by 5
Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer's Disease.
Maher, P. A. (2020) · PubMed Central · Cited by 5
Rastegari, A., Saeedi, M., Vahedi‐Mazdabadi, Y., Soleimani, M., Eftekhari, M., Akbarzadeh, T., & Khanavi, M. (2020) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22127/rjp.2020.223143.1565 · Cited by 5
Kuang, H., Liu, X., Tan, H., Zhang, Z., Zeng, B., & Wang, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-71837-x · Cited by 4
Challenges and opportunities in neurodegenerative diseases management
Syed, J. M., Nemichandra, S. C., Sridhar, S. B., Shareef, J., Ramesh, M., & Chalasani, S. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00026-x · Cited by 4
The Limitations of Using Cognitive Cutoff Scores for Enrollment in Alzheimer Trials
Patrick, R. E., Hobbs, K., Mathias, L., Harper, D. G., & Forester, B. P. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.02.014 · Cited by 4
Available Treatment Modules for Brain Disorders
Iman, T., Akram, R., Javed, M. S., Rasul, A., Sajid, F., Tehreem, A., Waris, S., & Hussain, G. (2023) · Food bioactive ingredients · doi:10.1007/978-3-031-41188-5_6 · Cited by 4
Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve
Niazi, S. K. (2024) · Biomedicines · doi:10.3390/biomedicines12122918 · Cited by 4
Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer’s Disease
Thiyagarajah, M. T., Herrmann, N., Ruthirakuhan, M. T., Li, A., & Lanctôt, K. L. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00181-6 · Cited by 4
Computational Neurology: Computational Modeling Approaches in Dementia
Wong‐Lin, K., Sánchez‐Bornot, J. M., McCombe, N., Kaur, D., McClean, P. L., Zou, X., Youssofzadeh, V., Ding, X., Bucholc, M., Yang, S., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11588-0 · Cited by 4
Jeong, J. H., Lee, S. E., Lee, J. H., Kim, H. D., Soe, K.-H., Kim, D. H., & Han, S. Y. (2020) · Anatomy & Cell Biology · doi:10.5115/acb.20.011 · Cited by 4
Lippi, S. L. P., Kakalec, P. A., Smith, M. L., & Flinn, J. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00854 · Cited by 4
Yang, T., Shi, Y. X., Lin, C., Yan, C., Zhang, D., & Lin, J. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.02.018 · Cited by 4
QSAR Modeling of Thirty Active Compounds for the Inhibition of the Acetylcholinesterase Enzyme
Hammoudi, N. E. H., Benguerba, Y., & Sobhi, W. (2019) · Current Research in Bioinformatics · doi:10.3844/ajbsp.2019.62.65 · Cited by 4
Baek, S., Park, S., Shin, J., Lee, J., Kim, H. Y., Han, G., & Kim, Y. S. (2020) · Applied Biological Chemistry · doi:10.1186/s13765-020-00507-z · Cited by 4
Kenning, G., & Brankaert, R. (2020) · Human-computer interaction series · doi:10.1007/978-3-030-32835-1_1 · Cited by 4
Cognitive Assessment of Japanese Older Adults with Text Data Augmentation
Igarashi, T., & Nihei, M. (2022) · Healthcare · doi:10.3390/healthcare10102051 · Cited by 4
Rexach, J. E., Swarup, V., Chang, T. S., & Geschwind, D. H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/597542 · Cited by 4
Song, S., Guo, Z., & Mu, Q. (2025) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000545553 · Cited by 3
Houzé, L., Dhénain, M., Lam, S., Petit, F., Haı̈k, S., Mouton‐Liger, F., Hugon, J., Dam, J., Paquet, C., Jockers, R., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01792-w · Cited by 3
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.3 · Cited by 1
Brain-First vs. Body-First Models in Neurodegenerative Disease: A Perspective Review
Forte, G., & Casagrande, M. (2026) · NeuroSci · doi:10.3390/neurosci7030057 · Cited by 3
Alotaibi, B. S., Saleem, U., Farrukh, M., Waseem, S., Chauhdary, Z., Alsharif, I., Al-Qahtani, W. S., Alanzi, A. R., BinMowyna, M. N., Shah, M. A., et al. (2024) · Italian Journal of Food Science · doi:10.15586/ijfs.v36i3.2643 · Cited by 3
Mechanistic insights into the molecular and cellular basis of Alzheimer's disease
Issa, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00013-0 · Cited by 3
Modeling neurodegenerative diseases by human pluripotent stem cell-induced brain organoid
Luo, X., Sun, R., Tian, F., Hao, J., & Hu, L. (2018) · Translational Surgery · doi:10.4103/ts.ts_4_18 · Cited by 3
Camins, A., Ettcheto, M., & Busquets, O. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.257513 · Cited by 3
Cao, H., Du, X., Zeng, R., Lv, Z., Ye, S., Jiang, P., Wang, Z., Ma, L., Huang, Y., Li, C., et al. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200102151731 · Cited by 3
Discovery of small molecules for the treatment of Alzheimer’s disease
Rao, P. P. N., Pham, A. T., & Shakeri, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818349-6.00011-x · Cited by 3
A Brief History of Psychopharmacology
Haddad, P. M., Nutt, D., & Green, A. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.003 · Cited by 3
Yusop, S. N. W., Imran, S., Adenan, M. I., & Sultan, S. (2020) · Steroids · doi:10.1016/j.steroids.2020.108735 · Cited by 3
Doenças negligenciadas e indústria farmacêutica: o caso da Doença de Chagas
da Silva, A. P., Dantas, G. M. S., da Silva, P. I. F., de Medeiros, A. N. G., & Nagashima, T. (2021) · Research Society and Development · doi:10.33448/rsd-v10i2.12419 · Cited by 3
Ethical Issues Which Have Prevented the U.S. from Maximizing Quality of Life Years
Arbor, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97561 · Cited by 3
Shim, Y., Han, H. J., Park, K. W., Kim, B. C., Park, K. H., Park, M. Y., Kim, H.-J., Moon, S. Y., Choi, S. H., Park, K. W., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215277 · Cited by 3
Treating Alzheimer's Disease : Combine or Fail ?
Bakchine, S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.16 · Cited by 3
Goldschmidt‐Clermont, P. J., Volinsky, F. G., LaRosa, S. P., Gilbert, J. R., & Pericak‐Vance, M. A. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz150 · Cited by 3
Anti-dementia medications: Fighting a losing battle?
Micov, A. M., & Pecikoza, U. B. (2020) · Arhiv za farmaciju · doi:10.5937/arhfarm2002055m · Cited by 3
Rodríguez, C. M. V., Meléndez, Y. E., & Flores‐Otero, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-61663-2_4 · Cited by 3
Frisoni, G. B., Blin, O. J., & Bordet, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190267 · Cited by 3
Hsien, L. C., Kaur, P., Teo, E., Lam, V. Y. M., Zhu, F., Kibat, C., Mathuru, A. S., Gruber, J., & Tolwinski, N. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/836593 · Cited by 3
A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTKPreprint
Samentar, L., Salazar, A., Pan, P., Etebar, K., Choy, K., Uddin, D., Eliseeff, P., Bugayong, A. M., Garrido, J. A. M. G., Emini, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.03.467048 · Cited by 2
Menon, S., & Rais, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-04435-0 · Cited by 2
Tabish, M., Malik, I., Ansarullah, S. I., & Alshahrani, A. (2025) · Journal of Disability Research · doi:10.57197/jdr-2025-0735 · Cited by 2
Mastnak-Sokolov, P., Knez, D., Meden, A., Benedik, N. S., Benetik, S. F., Rambaher, M. H., Zorman, M., Nachon, F., Brazzolotto, X., Jardemark, K. E., et al. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111830 · Cited by 3
Reed, C. C., Happich, M., Raskin, J., Tockhorn‐Heidenreich, A., & Belger, M. A. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.4 · Cited by 2
Pour une prise en charge préventive de la maladie d’Alzheimer
Dubois, B., Bombois, S., Villain, N., Teichmann, M., Epelbaum, S., Migliaccio, R., Genthon, R., VERRAT, B., Lesoil, C., Lévy, M., et al. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.04.012 · Cited by 5
Kinoshita, K., Nakabayashi, S., Ishikura, A., Fujihara, K., Hirabayashi, S., Koike, S., Sasaki, H., Ogasawara, Y., & Koyama, K. (2022) · Heterocycles · doi:10.3987/com-22-14711 · Cited by 3
Alzheimer’s Disease: Pathogenesis, Hypothesis and Management
Anjum, R. (2023) · Punjab University journal of zoology · doi:10.17582/journal.pujz/2023.38.2.229.236 · Cited by 2
Srinivasulu, P., Babu, J. R., Kumar, T. N. V. G., Kumar, P. P., & VIDYADHARA, S. (2021) · The Thai Journal of Pharmaceutical Sciences · doi:10.56808/3027-7922.2488 · Cited by 2
Zhang, H., Liang, S., Xu, T., Li, W., Huang, D., Dong, Y., Li, G., Miller, J. P., Goedegebuure, S. P., Sardiello, M., et al. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag355 · Cited by 4
Facteurs de risque de la maladie d’Alzheimer et des maladies apparentées : approche parcours de vie
Singh‐Manoux, A., & Sabia, S. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.01.015 · Cited by 4
Target Tau, not Amyloid, to Prevent and Treat Alzheimer’s Disease
Esiri, M. M. (2020) · OBM Geriatrics · doi:10.21926/obm.geriatr.2001103 · Cited by 2
The application of stratified medicine to dementia care
Sidhom, E., O'Brien, J. T., & Underwood, B. R. (2020) · BJPsych Advances · doi:10.1192/bja.2020.28 · Cited by 2
Algahtani, H. A., Shirah, B. H., Alshareef, A., Al-Qahtani, M. H., Abdulkareem, A. A., & Naseer, M. I. (2020) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2020.03033 · Cited by 2
Lyu, D., Shi, Y., & Lyu, X. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048453 · Cited by 2
Metadata
- Authors
- Cummings, J., Lee, G., Ritter, A., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Global Alzheimer's Platform Foundation (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 195-214
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6021548
- OpenAlex
- W2918066696
- Cited by
- 697
- References
- 48
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 39 · 2023: 22 · 2022: 55 · 2021: 138 · 2020: 177 · 2019: 170 · 2018: 42
- FWCI
- 91.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, disease-modifying therapy, amyloid biomarkers, prodromal Alzheimer's disease, preclinical Alzheimer's disease, neuropsychiatric symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
